What is pyroglutamic acid (5‑oxoproline)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Pyroglutamic Acid (5-Oxoproline)?

Pyroglutamic acid (5-oxoproline) is an organic acid intermediate in the gamma-glutamyl cycle of glutathione metabolism that serves as a diagnostic marker for glutathione synthetase deficiency and can accumulate pathologically due to medication effects, particularly acetaminophen. 1

Biochemical Identity and Normal Physiology

Pyroglutamic acid is a structural analog of the amino acid proline and represents a byproduct of glutathione metabolism within the gamma-glutamyl cycle. 2 Under normal physiological conditions, this compound is:

  • Continuously synthesized and broken down as an intermediate in glutathione metabolism 3
  • Efficiently reabsorbed in the kidney via sodium-coupled transport mechanisms, specifically through the monocarboxylate transporter SLC5A8 2
  • Present in small amounts in body fluids under normal circumstances 1

Clinical Significance as a Diagnostic Marker

Primary Metabolic Disorder

Elevated urinary pyroglutamic acid is a marker of glutathione synthetase deficiency, an autosomal recessive inborn error of metabolism. 1 The mechanism of overproduction involves:

  • Deficiency of glutathione synthetase leads to lack of glutathione, which normally provides feedback inhibition on gamma-glutamyl-cysteine synthetase 4
  • Excessive gamma-glutamyl-cysteine production occurs without this inhibition 4
  • Conversion to 5-oxoproline by gamma-glutamyl cyclotransferase exceeds the capacity of 5-oxoprolinase, causing accumulation 4

Acquired Elevation from Medications

Pyroglutamic acid elevation can occur secondary to treatment with acetaminophen, vigabatrin, and other medications, even at therapeutic doses. 1 This represents a critical diagnostic pitfall:

  • Acetaminophen is the most common culprit, causing elevation through glutathione and cysteine depletion that activates an ATP-depleting futile 5-oxoproline cycle 5, 3
  • Typical patient profile: malnourished, chronically ill women with therapeutic or low acetaminophen levels (not toxic range) 5, 6
  • Common co-factors: flucloxacillin co-prescription (one-third of cases), renal dysfunction, sepsis, malnutrition, and pregnancy 7, 3, 8
  • Clinical presentation: high anion gap metabolic acidosis (anion gap 14-30 mEq/L), confusion, nausea, vomiting, and hypokalaemia in one-third of cases 7, 9, 3

Laboratory Detection and Interpretation

Pyroglutamic acid is detected through urine organic acid analysis by gas chromatography-mass spectrometry (GC-MS). 1 Critical analytical considerations include:

  • Urine specimens should be collected during acute illness when diagnostic metabolites are highest, frozen immediately, and stored at -20°C or lower 1
  • In-source fragmentation can create false positives: glutamine and glutamate can cyclize to pyroglutamate during electrospray ionization, producing peaks at different retention times that must be distinguished from true biological pyroglutamate 10
  • Isotopic tracer studies amplify interference: 13C3 pyroglutamate mass differs from 13C0 asparagine by only 6 ppm, requiring high-resolution mass spectrometry 10

Clinical Context for Interpretation

Clinical history, diet, and medication must be considered to determine if pyroglutamic acid elevation is relevant to the clinical presentation. 1 The American College of Medical Genetics and Genomics emphasizes that:

  • Exogenous variables significantly affect organic acid profiles, including medications like valproate, levetiracetam, aspirin, and ibuprofen 1
  • Sample contamination and bacterial metabolism can produce misleading results, particularly with prolonged storage at ambient temperature 1
  • Pattern recognition is essential: diagnosis relies on determining the presence or absence of expected compounds in context 1

Management Implications

When acquired pyroglutamic acidosis is identified:

  • Immediate cessation of acetaminophen and flucloxacillin (if present) is therapeutic 3, 6, 8
  • Intravenous fluid administration is the mainstay of treatment 7, 6
  • N-acetylcysteine administration has compelling biochemical justification (replenishes glutathione/cysteine) though clinical evidence is anecdotal 5, 3, 6
  • Prognosis is excellent with prompt recognition and withdrawal of causative agents—the condition is entirely reversible 8

References

Research

Pyroglutamate acidosis 2023. A review of 100 cases.

Clinical medicine (London, England), 2024

Research

On the mechanism of 5-oxoproline overproduction in 5-oxoprolinuria.

Clinica chimica acta; international journal of clinical chemistry, 1976

Research

A Review Article on 5-Oxoproline Induced High Anion Gap Metabolic Acidosis.

South Dakota medicine : the journal of the South Dakota State Medical Association, 2021

Research

Acetaminophen-induced anion gap metabolic acidosis and 5-oxoprolinuria (pyroglutamic aciduria) acquired in hospital.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005

Research

Pyroglutamic acidosis in association with therapeutic paracetamol use.

Clinical medicine (London, England), 2016

Related Questions

What is the treatment for a 2-year-old with vomiting and high anion gap metabolic acidosis?
What are the differential diagnoses for a patient with type 2 diabetes and a history of cannabis use who develops recurrent anion gap acidosis despite initial treatment with insulin and fluid resuscitation?
Can aspirin (acetylsalicylic acid) cause high anion gap metabolic acidosis in a post-hip replacement surgery patient taking it for venous thromboembolism prophylaxis or cardiovascular indications?
Can Mounjaro (tirzepatide) cause high anion gap metabolic acidosis?
What causes high anion gap metabolic alkalosis?
What is the clinical significance of an elevated haptoglobin level of 206 mg/dL in an asymptomatic patient?
What are the treatment options and recommendations for Hailey-Hailey disease?
Why use fluoxetine (Prozac) 90 mg weekly in a patient who has been stabilized on daily fluoxetine 20 mg for 2–4 weeks with good tolerability?
What are the possible causes and recommended evaluation for a patient with elevated red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, and mean corpuscular hemoglobin?
How should I obtain and interpret a real‑time PCR test for Bordetella pertussis?
In an adult patient stable on lisdexamfetamine (Vyvanse) 30 mg for ADHD, recently started on escitalopram (Lexapro) 5 mg and taking trazodone 100 mg nightly, who now presents with acute hypomania and severe sleep deprivation (≈2 hours/night for 4–5 days) after serotonin syndrome has been ruled out, how should I manage the situation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.